이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

새로 진단된 교모세포종 환자 치료에서 선량 증량된 광자 IMRT 또는 양성자 빔 방사선 요법 대 표준 선량 방사선 요법 및 테모졸로마이드

2026년 9월 9일 업데이트: NRG Oncology

새로 진단된 교모세포종 환자에서 Temozolomide 병용 및 보조제를 사용한 저분할 용량 증량 광자 IMRT 또는 양성자 빔 요법 대 기존 광자 조사의 무작위 2상 시험

This randomized phase II trial studies how well dose-escalated photon intensity-modulated radiation therapy (IMRT) or proton beam radiation therapy works compared with standard-dose radiation therapy when given with temozolomide in patients with newly diagnosed glioblastoma. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs, such as temozolomide, may make tumor cells more sensitive to radiation therapy. It is not yet known whether dose-escalated photon IMRT or proton beam radiation therapy is more effective than standard-dose radiation therapy with temozolomide in treating glioblastoma.

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

상세 설명

PRIMARY OBJECTIVE:

I. To determine if dose-escalated and -intensified photon IMRT or proton beam therapy (using a dose-per-fraction escalation with simultaneous integrated boost) with concomitant and adjuvant temozolomide improves overall survival, as compared to standard-dose photon irradiation with concomitant and adjuvant temozolomide.

SECONDARY OBJECTIVES:

I. To indirectly compare dose-escalated and -intensified photon IMRT to dose-escalated and -intensified proton beam therapy in terms of overall survival.

II. To indirectly compare and record toxicities of dose-escalated and -intensified photon IMRT versus dose-escalated and -intensified proton beam therapy and directly compare the toxicities of these approaches versus standard-dose photon irradiation on the backbone of concomitant and adjuvant temozolomide.

III. To determine if dose-escalated and -intensified IMRT or proton beam therapy (using a dose-per-fraction escalation with simultaneous integrated boost) with concomitant and adjuvant temozolomide improves perceived cognitive symptom severity, as compared to standard-dose photon irradiation with concomitant and adjuvant temozolomide.

IV. To determine if dose-escalated and -intensified photon IMRT or proton beam therapy (using a dose-per-fraction escalation with simultaneous integrated boost) with concomitant and adjuvant temozolomide improves neurocognitive function, as compared to standard-dose photon irradiation with concomitant and adjuvant temozolomide.

V. To indirectly determine if dose-escalated and -intensified proton beam therapy with concomitant and adjuvant temozolomide improves perceived cognitive symptom severity, as compared to dose-escalated and -intensified photon IMRT, and to directly compare symptom burden with these approaches versus standard-dose photon irradiation on the backbone of concomitant and adjuvant temozolomide.

VI. To indirectly determine if dose-escalated and -intensified proton beam therapy with concomitant and adjuvant temozolomide improves neurocognitive function, as compared to dose-escalated and -intensified photon IMRT, and to directly compare neurocognitive function with these approaches versus standard-dose photon irradiation on the backbone of concomitant and adjuvant temozolomide.

EXPLORATORY OBJECTIVES:

I. Tissue banking for future translational science projects that will be determined based on the state of the science at the time the primary endpoint is reported and will be submitted to National Cancer Institute (NCI) for review and approval.

II. To prospectively compare CD4 lymphopenia between dose-escalated and intensified proton beam therapy, dose-escalated and -intensified photon IMRT, and standard-dose photon irradiation and determine whether CD4 lymphopenia impacts overall survival.

III. To explore the most appropriate and clinically relevant technological parameters to ensure quality and effectiveness throughout radiation therapy processes, including imaging, simulation, patient immobilization, target and critical structure definition, treatment planning, image guidance and delivery.

IIIa. To establish feasibility and clinical relevancy of quality assurance guidelines.

IIIb. To evaluate efficacy of quality assurance tools. IV. To explore the most appropriate and clinically relevant advanced and standard magnetic resonance imaging (MRI) imaging parameters.

IVa. To evaluate the feasibility of differentiating pseudo-progression and true progression in a multi institutional setting using magnetic resonance (MR) diffusion and perfusion imaging.

IVb. To evaluate for early, imaging biomarkers of response and overall survival.

OUTLINE: Patients are assigned to 1 of 2 groups depending on enrolling institution. Within each group, patients will be randomized 1:2 in favor of the experimental arms.

GROUP 1 = PHOTON IMRT CENTERS. GROUP 2 = PROTON CENTERS.

After completion of study treatment, patients are followed up every 3 months for 1 year, every 4 months for 1 year, and then every 6 months thereafter.

연구 유형

중재적

등록 (실제)

624

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

  • 미국
    • Alabama
      • Birmingham, Alabama, 미국, 35233
        • University of Alabama at Birmingham Cancer Center
    • Arizona
      • Phoenix, Arizona, 미국, 85054
        • Mayo Clinic Hospital in Arizona
      • Phoenix, Arizona, 미국, 85013
        • Saint Joseph's Hospital and Medical Center
      • Scottsdale, Arizona, 미국, 85259
        • Mayo Clinic in Arizona
      • Tucson, Arizona, 미국, 85719
        • Banner University Medical Center - Tucson
      • Tucson, Arizona, 미국, 85704
        • Arizona Oncology Associates-West Orange Grove
    • Arkansas
      • Little Rock, Arkansas, 미국, 72205
        • University of Arkansas for Medical Sciences
    • California
      • Auburn, California, 미국, 95603
        • Sutter Cancer Centers Radiation Oncology Services-Auburn
      • Bakersfield, California, 미국, 93301
        • AIS Cancer Center at San Joaquin Community Hospital
      • Berkeley, California, 미국, 94704
        • Alta Bates Summit Medical Center-Herrick Campus
      • Cameron Park, California, 미국, 95682
        • Sutter Cancer Centers Radiation Oncology Services-Cameron Park
      • Castro Valley, California, 미국, 94546
        • Eden Hospital Medical Center
      • Fresno, California, 미국, 93720
        • Fresno Cancer Center
      • Greenbrae, California, 미국, 94904
        • Marin General Hospital
      • Loma Linda, California, 미국, 92354
        • Loma Linda University Medical Center
      • Los Angeles, California, 미국, 90033
        • USC / Norris Comprehensive Cancer Center
      • Los Angeles, California, 미국, 90048
        • Cedars Sinai Medical Center
      • Los Angeles, California, 미국, 90033
        • Los Angeles General Medical Center
      • Marysville, California, 미국, 95901
        • Fremont - Rideout Cancer Center
      • Modesto, California, 미국, 95355
        • Memorial Medical Center
      • Oakland, California, 미국, 94611
        • Kaiser Permanente Oakland-Broadway
      • Orange, California, 미국, 92868
        • UC Irvine Health/Chao Family Comprehensive Cancer Center
      • Orange, California, 미국, 92868
        • Saint Joseph Hospital - Orange
      • Palo Alto, California, 미국, 94301
        • Palo Alto Medical Foundation Health Care
      • Pomona, California, 미국, 91767
        • Pomona Valley Hospital Medical Center
      • Rancho Cordova, California, 미국, 95670
        • Kaiser Permanente-Rancho Cordova Cancer Center
      • Rohnert Park, California, 미국, 94928
        • Rohnert Park Cancer Center
      • Roseville, California, 미국, 95678
        • The Permanente Medical Group-Roseville Radiation Oncology
      • Roseville, California, 미국, 95661
        • Sutter Cancer Centers Radiation Oncology Services-Roseville
      • Sacramento, California, 미국, 95816
        • Sutter Medical Center Sacramento
      • Sacramento, California, 미국, 95817
        • University of California Davis Comprehensive Cancer Center
      • Sacramento, California, 미국, 95823
        • South Sacramento Cancer Center
      • San Francisco, California, 미국, 94115
        • California Pacific Medical Center-Pacific Campus
      • Santa Cruz, California, 미국, 95065
        • Palo Alto Medical Foundation-Santa Cruz
      • South San Francisco, California, 미국, 94080
        • Kaiser Permanente Cancer Treatment Center
      • Sunnyvale, California, 미국, 94086
        • Palo Alto Medical Foundation-Sunnyvale
      • Walnut Creek, California, 미국, 94598
        • John Muir Medical Center-Walnut Creek
    • Colorado
      • Colorado Springs, Colorado, 미국, 80909
        • UCHealth Memorial Hospital Central
      • Fort Collins, Colorado, 미국, 80524
        • Poudre Valley Hospital
    • Connecticut
      • Hartford, Connecticut, 미국, 06102
        • Hartford Hospital
    • Florida
      • Boca Raton, Florida, 미국, 33486
        • Boca Raton Regional Hospital
      • Gainesville, Florida, 미국, 32610
        • UF Health Cancer Institute - Gainesville
      • Jacksonville, Florida, 미국, 32207
        • Baptist MD Anderson Cancer Center
      • Jacksonville, Florida, 미국, 32209
        • University of Florida Health Science Center - Jacksonville
      • Jacksonville, Florida, 미국, 32258
        • Baptist Medical Center South
      • Miami, Florida, 미국, 33176
        • Miami Cancer Institute
      • Tampa, Florida, 미국, 33612
        • Moffitt Cancer Center
    • Georgia
      • Atlanta, Georgia, 미국, 30308
        • Emory University Hospital Midtown
      • Atlanta, Georgia, 미국, 30322
        • Emory University Hospital/Winship Cancer Institute
      • Atlanta, Georgia, 미국, 30308
        • Emory Proton Therapy Center
      • Savannah, Georgia, 미국, 31405
        • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
    • Idaho
      • Boise, Idaho, 미국, 83706
        • Saint Alphonsus Cancer Care Center-Boise
    • Illinois
      • Chicago, Illinois, 미국, 60611
        • Northwestern University
      • Chicago, Illinois, 미국, 60637
        • University of Chicago Comprehensive Cancer Center
      • Chicago, Illinois, 미국, 60612
        • John H Stroger Jr Hospital of Cook County
      • Chicago, Illinois, 미국, 60612
        • Rush MD Anderson Cancer Center
      • DeKalb, Illinois, 미국, 60115
        • Northwestern Medicine Cancer Center Kishwaukee
      • Decatur, Illinois, 미국, 62526
        • Decatur Memorial Hospital
      • Geneva, Illinois, 미국, 60134
        • Northwestern Medicine Cancer Center Delnor
      • New Lenox, Illinois, 미국, 60451
        • UC Comprehensive Cancer Center at Silver Cross
      • Park Ridge, Illinois, 미국, 60068
        • Advocate Lutheran General Hospital
      • Peoria, Illinois, 미국, 61637
        • OSF Saint Francis Medical Center
      • Springfield, Illinois, 미국, 62781
        • Springfield Memorial Hospital
      • Warrenville, Illinois, 미국, 60555
        • Northwestern Medicine Cancer Center Warrenville
    • Indiana
      • Fort Wayne, Indiana, 미국, 46805
        • Parkview Hospital Randallia
      • Fort Wayne, Indiana, 미국, 46845
        • Parkview Regional Medical Center
      • Fort Wayne, Indiana, 미국, 46804
        • Radiation Oncology Associates PC
      • Indianapolis, Indiana, 미국, 46219
        • Community Cancer Center East
      • Indianapolis, Indiana, 미국, 46227
        • Community Cancer Center South
      • Indianapolis, Indiana, 미국, 46256
        • Community Cancer Center North
      • Indianapolis, Indiana, 미국, 46202
        • IU Health Methodist Hospital
      • Muncie, Indiana, 미국, 47303
        • IU Health Ball Memorial Hospital
    • Iowa
      • Cedar Rapids, Iowa, 미국, 52403
        • Mercy Hospital
      • Des Moines, Iowa, 미국, 50309
        • Iowa Methodist Medical Center
    • Kansas
      • Kansas City, Kansas, 미국, 66160
        • University of Kansas Cancer Center
      • Overland Park, Kansas, 미국, 66210
        • University of Kansas Cancer Center-Overland Park
    • Kentucky
      • Louisville, Kentucky, 미국, 40202
        • Norton Hospital Pavilion and Medical Campus
    • Louisiana
      • New Orleans, Louisiana, 미국, 70121
        • Ochsner Medical Center Jefferson
      • Shreveport, Louisiana, 미국, 71103
        • Willis-Knighton Medical and Cancer Center
    • Maryland
      • Baltimore, Maryland, 미국, 21201
        • University of Maryland/Greenebaum Cancer Center
      • Baltimore, Maryland, 미국, 21201
        • Maryland Proton Treatment Center
      • Bel Air, Maryland, 미국, 21014
        • UM Upper Chesapeake Medical Center
      • Columbia, Maryland, 미국, 21044
        • Central Maryland Radiation Oncology in Howard County
      • Glen Burnie, Maryland, 미국, 21061
        • UM Baltimore Washington Medical Center/Tate Cancer Center
    • Massachusetts
      • Boston, Massachusetts, 미국, 02111
        • Tufts Medical Center
      • Boston, Massachusetts, 미국, 02118
        • Boston Medical Center
      • Boston, Massachusetts, 미국, 02114
        • Massachusetts General Hospital Cancer Center
      • Danvers, Massachusetts, 미국, 01923
        • Mass General/North Shore Cancer Center
      • Lowell, Massachusetts, 미국, 01854
        • Lowell General Hospital
    • Michigan
      • Ann Arbor, Michigan, 미국, 48109
        • University of Michigan Rogel Cancer Center
      • Ann Arbor, Michigan, 미국, 48106
        • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
      • Bay City, Michigan, 미국, 48706
        • McLaren Cancer Institute-Bay City
      • Dearborn, Michigan, 미국, 48124
        • Corewell Health Dearborn Hospital
      • Detroit, Michigan, 미국, 48202
        • Henry Ford Hospital
      • Flint, Michigan, 미국, 48532
        • McLaren Cancer Institute-Flint
      • Grand Rapids, Michigan, 미국, 49503
        • Trinity Health Grand Rapids Hospital
      • Grand Rapids, Michigan, 미국, 49503
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
      • Kalamazoo, Michigan, 미국, 49007
        • West Michigan Cancer Center
      • Lapeer, Michigan, 미국, 48446
        • McLaren Cancer Institute-Lapeer Region
      • Livonia, Michigan, 미국, 48154
        • Trinity Health Saint Mary Mercy Livonia Hospital
      • Mount Clemens, Michigan, 미국, 48043
        • McLaren Cancer Institute-Macomb
      • Mount Pleasant, Michigan, 미국, 48858
        • McLaren Cancer Institute-Central Michigan
      • Owosso, Michigan, 미국, 48867
        • McLaren Cancer Institute-Owosso
      • Petoskey, Michigan, 미국, 49770
        • McLaren Cancer Institute-Northern Michigan
      • Pontiac, Michigan, 미국, 48341
        • Trinity Health Saint Joseph Mercy Oakland Hospital
      • Royal Oak, Michigan, 미국, 48073
        • Corewell Health William Beaumont University Hospital
      • Saint Joseph, Michigan, 미국, 49085
        • Corewell Health Lakeland Hospitals - Saint Joseph Hospital
      • Troy, Michigan, 미국, 48085
        • Corewell Health Beaumont Troy Hospital
    • Minnesota
      • Bemidji, Minnesota, 미국, 56601
        • Sanford Joe Lueken Cancer Center
      • Duluth, Minnesota, 미국, 55805
        • Saint Luke's Hospital of Duluth
      • Rochester, Minnesota, 미국, 55905
        • Mayo Clinic in Rochester
      • Saint Cloud, Minnesota, 미국, 56303
        • Coborn Cancer Center at Saint Cloud Hospital
      • Saint Paul, Minnesota, 미국, 55101
        • Regions Hospital
    • Mississippi
      • Jackson, Mississippi, 미국, 39216
        • University of Mississippi Medical Center
    • Missouri
      • Kansas City, Missouri, 미국, 64154
        • University of Kansas Cancer Center - North
      • Kansas City, Missouri, 미국, 64116
        • North Kansas City Hospital
      • St Louis, Missouri, 미국, 63110
        • Washington University School of Medicine
    • Montana
      • Billings, Montana, 미국, 59101
        • Billings Clinic Cancer Center
    • Nevada
      • Las Vegas, Nevada, 미국, 89148
        • Comprehensive Cancer Centers of Nevada
      • Reno, Nevada, 미국, 89502
        • Renown Regional Medical Center
      • Reno, Nevada, 미국, 89503
        • Saint Mary's Regional Medical Center
    • New Hampshire
      • Lebanon, New Hampshire, 미국, 03756
        • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
    • New Jersey
      • Basking Ridge, New Jersey, 미국, 07920
        • Memorial Sloan Kettering Basking Ridge
      • New Brunswick, New Jersey, 미국, 08903
        • Rutgers Cancer Institute of New Jersey
      • New Brunswick, New Jersey, 미국, 08903
        • Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
      • Pennington, New Jersey, 미국, 08534
        • Capital Health Medical Center-Hopewell
      • Somerset, New Jersey, 미국, 08873
        • ProCure Proton Therapy Center-Somerset
      • Voorhees Township, New Jersey, 미국, 08043
        • Virtua Voorhees
    • New York
      • Brooklyn, New York, 미국, 11215
        • New York-Presbyterian/Brooklyn Methodist Hospital
      • Commack, New York, 미국, 11725
        • Memorial Sloan Kettering Commack
      • Harrison, New York, 미국, 10604
        • Memorial Sloan Kettering Westchester
      • Lake Success, New York, 미국, 11042
        • Northwell Health/Center for Advanced Medicine
      • New York, New York, 미국, 10065
        • Memorial Sloan Kettering Cancer Center
      • New York, New York, 미국, 10032
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
      • New York, New York, 미국, 10016
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
      • The Bronx, New York, 미국, 10467
        • Montefiore Medical Center - Moses Campus
    • North Carolina
      • Asheville, North Carolina, 미국, 28801
        • Mission Hospital
      • Winston-Salem, North Carolina, 미국, 27157
        • Wake Forest University Health Sciences
      • Winston-Salem, North Carolina, 미국, 27103
        • Novant Health Forsyth Medical Center
    • North Dakota
      • Bismarck, North Dakota, 미국, 58501
        • Sanford Bismarck Medical Center
      • Fargo, North Dakota, 미국, 58122
        • Sanford Roger Maris Cancer Center
    • Ohio
      • Akron, Ohio, 미국, 44307
        • Cleveland Clinic Akron General
      • Beachwood, Ohio, 미국, 44122
        • UHHS-Chagrin Highlands Medical Center
      • Chardon, Ohio, 미국, 44024
        • Geauga Hospital
      • Cincinnati, Ohio, 미국, 45219
        • University of Cincinnati Cancer Center-UC Medical Center
      • Cleveland, Ohio, 미국, 44106
        • Case Western Reserve University
      • Cleveland, Ohio, 미국, 44195
        • Cleveland Clinic Foundation
      • Cleveland, Ohio, 미국, 44111
        • Cleveland Clinic Cancer Center/Fairview Hospital
      • Columbus, Ohio, 미국, 43214
        • Riverside Methodist Hospital
      • Columbus, Ohio, 미국, 43210
        • Ohio State University Comprehensive Cancer Center
      • Elyria, Ohio, 미국, 44035
        • Mercy Cancer Center-Elyria
      • Independence, Ohio, 미국, 44131
        • Cleveland Clinic Cancer Center Independence
      • Mayfield Heights, Ohio, 미국, 44124
        • Hillcrest Hospital Cancer Center
      • Mentor, Ohio, 미국, 44060
        • UH Seidman Cancer Center at Lake Health Mentor Campus
      • Middleburg Heights, Ohio, 미국, 44130
        • UH Seidman Cancer Center at Southwest General Hospital
      • Parma, Ohio, 미국, 44129
        • University Hospitals Parma Medical Center
      • Sandusky, Ohio, 미국, 44870
        • North Coast Cancer Care
      • Sandusky, Ohio, 미국, 44870
        • UH Seidman Cancer Center at Firelands Regional Medical Center
      • Strongsville, Ohio, 미국, 44136
        • Cleveland Clinic Cancer Center Strongsville
      • Toledo, Ohio, 미국, 43614
        • University of Toledo
      • West Chester, Ohio, 미국, 45069
        • University of Cincinnati Cancer Center-West Chester
      • Westlake, Ohio, 미국, 44145
        • UHHS-Westlake Medical Center
      • Wooster, Ohio, 미국, 44691
        • Cleveland Clinic Wooster Family Health and Surgery Center
    • Oklahoma
      • Oklahoma City, Oklahoma, 미국, 73104
        • University of Oklahoma Health Sciences Center
    • Oregon
      • Eugene, Oregon, 미국, 97401
        • Willamette Valley Cancer Center
      • Gresham, Oregon, 미국, 97030
        • Legacy Mount Hood Medical Center
      • Portland, Oregon, 미국, 97210
        • Legacy Good Samaritan Hospital and Medical Center
    • Pennsylvania
      • Bethlehem, Pennsylvania, 미국, 18015
        • Saint Luke's University Hospital-Bethlehem Campus
      • Dunmore, Pennsylvania, 미국, 18512
        • Northeast Radiation Oncology Center
      • Ephrata, Pennsylvania, 미국, 17522
        • Ephrata Cancer Center
      • Gettysburg, Pennsylvania, 미국, 17325
        • Adams Cancer Center
      • Harrisburg, Pennsylvania, 미국, 17109
        • UPMC Pinnacle Cancer Center/Community Osteopathic Campus
      • Lebanon, Pennsylvania, 미국, 17042
        • Sechler Family Cancer Center
      • Philadelphia, Pennsylvania, 미국, 19107
        • Thomas Jefferson University Hospital
      • Philadelphia, Pennsylvania, 미국, 19114
        • Jefferson Torresdale Hospital
      • Philadelphia, Pennsylvania, 미국, 19104
        • University of Pennsylvania/Abramson Cancer Center
      • West Reading, Pennsylvania, 미국, 19611
        • Reading Hospital
      • York, Pennsylvania, 미국, 17403
        • WellSpan Health-York Cancer Center
    • South Carolina
      • Boiling Springs, South Carolina, 미국, 29316
        • Prisma Health Cancer Institute - Spartanburg
      • Charleston, South Carolina, 미국, 29425
        • Medical University of South Carolina
      • Greenville, South Carolina, 미국, 29605
        • Prisma Health Cancer Institute - Faris
      • Greenville, South Carolina, 미국, 29615
        • Prisma Health Cancer Institute - Eastside
      • Greenwood, South Carolina, 미국, 29646
        • Self Regional Healthcare
      • Greer, South Carolina, 미국, 29650
        • Prisma Health Cancer Institute - Greer
      • Seneca, South Carolina, 미국, 29672
        • Prisma Health Cancer Institute - Seneca
    • South Dakota
      • Sioux Falls, South Dakota, 미국, 57117-5134
        • Sanford USD Medical Center - Sioux Falls
    • Tennessee
      • Knoxville, Tennessee, 미국, 37909
        • Tennessee Cancer Specialists-Dowell Springs
    • Texas
      • Austin, Texas, 미국, 78701
        • Dell Seton Medical Center at The University of Texas
      • Austin, Texas, 미국, 78702
        • Austin Cancer Centers-Central Austin
      • Austin, Texas, 미국, 78705
        • Texas Oncology-Austin Midtown
      • Austin, Texas, 미국, 78731
        • Texas Oncology - Central Austin Cancer Center
      • Austin, Texas, 미국, 78745
        • Texas Oncology - South Austin Cancer Center
      • Austin, Texas, 미국, 78758
        • Austin Cancer Centers-North
      • Dallas, Texas, 미국, 75390
        • UT Southwestern/Simmons Cancer Center-Dallas
      • Denison, Texas, 미국, 75020
        • Texas Oncology - Denison Cancer Center
      • Flower Mound, Texas, 미국, 75028
        • Texas Oncology-Flower Mound
      • Fort Worth, Texas, 미국, 76104
        • Texas Oncology - Fort Worth Cancer Center
      • Galveston, Texas, 미국, 77555-0565
        • University of Texas Medical Branch
      • Houston, Texas, 미국, 77030
        • M D Anderson Cancer Center
      • Houston, Texas, 미국, 77024
        • Memorial Hermann Memorial City Medical Center
      • League City, Texas, 미국, 77573
        • UTMB Cancer Center at Victory Lakes
      • Lubbock, Texas, 미국, 79410
        • Covenant Medical Center-Lakeside
      • Round Rock, Texas, 미국, 78665
        • Texas Oncology-Seton Williamson
      • Round Rock, Texas, 미국, 78681
        • Texas Oncology - Round Rock Cancer Center
      • San Antonio, Texas, 미국, 78229
        • University of Texas Health Science Center at San Antonio
      • Sugar Land, Texas, 미국, 77479
        • Texas Oncology Cancer Center Sugar Land
      • Tyler, Texas, 미국, 75702
        • Texas Oncology - Tyler
    • Utah
      • Logan, Utah, 미국, 84321
        • Logan Regional Hospital
      • Murray, Utah, 미국, 84107
        • Intermountain Medical Center
      • Ogden, Utah, 미국, 84403
        • McKay-Dee Hospital Center
      • Provo, Utah, 미국, 84604
        • Utah Valley Regional Medical Center
      • Salt Lake City, Utah, 미국, 84112
        • Huntsman Cancer Institute/University of Utah
      • St. George, Utah, 미국, 84770
        • Saint George Regional Medical Center
    • Vermont
      • Berlin Corners, Vermont, 미국, 05602
        • Central Vermont Medical Center/National Life Cancer Treatment
      • Burlington, Vermont, 미국, 05401
        • University of Vermont Medical Center
      • Saint Johnsbury, Vermont, 미국, 05819
        • Dartmouth Cancer Center - North
    • Virginia
      • Richmond, Virginia, 미국, 23298
        • VCU Massey Comprehensive Cancer Center
    • Washington
      • Seattle, Washington, 미국, 98195
        • University of Washington Medical Center - Montlake
      • Seattle, Washington, 미국, 98133
        • FHCC at Northwest Hospital
      • Seattle, Washington, 미국, 98133
        • FHCC Proton Therapy Center
      • Vancouver, Washington, 미국, 98686
        • Legacy Salmon Creek Hospital
      • Vancouver, Washington, 미국, 98684
        • Compass Oncology Vancouver
    • West Virginia
      • Wheeling, West Virginia, 미국, 26003
        • Wheeling Hospital/Schiffler Cancer Center
    • Wisconsin
      • Antigo, Wisconsin, 미국, 54409
        • Langlade Hospital and Cancer Center
      • La Crosse, Wisconsin, 미국, 54601
        • Gundersen Lutheran Medical Center
      • Madison, Wisconsin, 미국, 53792
        • University of Wisconsin Carbone Cancer Center - University Hospital
      • Menomonee Falls, Wisconsin, 미국, 53051
        • Froedtert Menomonee Falls Hospital
      • Milwaukee, Wisconsin, 미국, 53226
        • Medical College of Wisconsin
      • Waukesha, Wisconsin, 미국, 53188
        • UW Cancer Center at ProHealth Care
      • Wausau, Wisconsin, 미국, 54401
        • Aspirus Regional Cancer Center
  • 캐나다
    • British Columbia
      • Victoria, British Columbia, 캐나다, V8R 6V5
        • BCCA-Vancouver Island Cancer Centre
    • Ontario
      • Ottawa, Ontario, 캐나다, K1H 8L6
        • Ottawa Hospital and Cancer Center-General Campus
      • Windsor, Ontario, 캐나다, N8W 2X3
        • Windsor Regional Cancer Centre
    • Quebec
      • Montreal, Quebec, 캐나다, H3H 2R9
        • The Research Institute of the McGill University Health Centre (MUHC)
      • Montreal, Quebec, 캐나다, H2X 3E4
        • CHUM - Centre Hospitalier de l'Universite de Montreal
      • Québec, Quebec, 캐나다, G1R 2J6
        • CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)
    • Saskatchewan
      • Saskatoon, Saskatchewan, 캐나다, S7N 4H4
        • Saskatoon Cancer Centre

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • PRIOR TO STEP 1 REGISTRATION

  • A diagnostic contrast-enhanced MRI (no other scan type allowed) of the brain must be performed postoperatively; the residual enhancing tumor and/or resection cavity must have a maximal diameter of 5 cm or less; the tumor diameter will be the greatest diameter as measured on the contrast-enhanced postoperative MRI and will include residual disease and/or the postoperative surgical cavity as appropriate

    • The postoperative brain MRI should be obtained within 72 hours of resection; if it is not obtained within 72 hours post-resection, then an MRI obtained 2 weeks or longer after surgery is required and can be utilized to ensure maximal diameter of residual tumor and/or resection cavity is 5 cm or less
    • For cases where a gross total resection of enhancing tumor is performed, but postoperative surgical cavity is NOT identifiable, the patient will be excluded from the trial

  • Tumor tissue must be available for submission for central pathology review

    • Timing requirements:

      • If MGMT has been assessed locally by LabCorps or MD Anderson Cancer Center Molecular Diagnostics Lab (MDACC-MDL):

        • Tissue for central pathology review and central MGMT assessment and the official LabCorps or MDACC-MDL MGMT result must be received by the NRG Oncology Biospecimen Bank on or before postoperative calendar day 40
        • The site's local MGMT report from LabCorp or MDACC-MDL will then be used to stratify the patient; a post-stratification MGMT central review will be performed, but step 2 registration and protocol treatment can proceed without central review of MGMT
        • Patients whose tissue for central pathology review and official LabCorps or MDACC-MDL MGMT result cannot be received by NRG Oncology Biospecimen Bank on or before 40 calendar days after surgery may NOT enroll on this trial, as central pathology review and stratification will not be complete in time for the patient to start treatment within 49 calendar days following surgery

      • If MGMT has not been assessed locally by LabCorps or MDACC-MDL:

        • Tissue for central pathology review and central MGMT assessment must be received by the NRG Oncology Biospecimen Bank on or before postoperative calendar day 30
        • Central MGMT analysis will be performed at MDACC-MDL and used for patient stratification; results will be conveyed to NRG Oncology within 10 business days of receipt of the tissue
        • Patients who have not had local MGMT assessment by LabCorps or MDACC-MDL and whose tissue for central pathology review cannot be received by NRG Oncology Biospecimen Bank on or before 30 calendar days after surgery may NOT enroll on this trial, as central pathology review and stratification will not be complete in time for the patient to start treatment within 49 calendar days following surgery

    • Tissue Requirements:

      • Patients must have at least 1 block of tumor tissue; submission of 2 blocks is strongly encouraged to maximize the chances of eligibility; in total, at least 1 cubic centimeter of tissue composed primarily of tumor must be present
      • Submission of an accompanying hematoxylin and eosin H&E slide(s) is MANDATORY
      • Diagnosis must be made by surgical excision, either partial or complete; stereotactic biopsy and cavitronic ultrasonic surgical (CUSA) techniques are not allowed

  • The tumor must be located in the supratentorial compartment only (any component involving the brain stem or cerebellum is not allowed)

  • Patients must provide study-specific informed consent prior to step 1 registration

  • PRIOR TO STEP 2 REGISTRATION

  • Histologically proven diagnosis of glioblastoma (World Health Organization [WHO] grade IV) confirmed by central review prior to step 2 registration

  • Tumor tissue that is determined by central pathology review prior to step 2 registration to be of sufficient quantity for central analysis of MGMT status

  • History/physical examination within 28 days prior to step 2 registration

  • The patient must have recovered from effects of surgery, postoperative infection, and other complications within 28 days prior to step 2 registration

  • Documentation of steroid doses within 28 days prior to step 2 registration

  • Karnofsky performance status >= 70 within 28 days prior to step 2 registration

  • Age >= 18

  • Complete blood count (CBC)/differential obtained within 28 days prior to step 2 registration

  • Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 (obtained within 28 days prior to step 2 registration)

  • Platelets >= 100,000 cells/mm^3 (obtained within 28 days prior to step 2 registration)

  • Hemoglobin >= 10.0 g/dl (obtained within 28 days prior to step 2 registration) (note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 10.0 g/dl is acceptable)

  • Bilirubin =< 1.5 upper limit of normal (ULN) (within 28 days prior to step 2 registration)

  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (within 28 days prior to step 2 registration)

  • Negative serum pregnancy test obtained for females of child-bearing potential within 28 days prior to step 2 registration

  • As of Amendment 2, if the registering site is a photon center (registering patients to group I), the patient must agree to participate in the advanced imaging sub-study

Exclusion Criteria:

  • Prior invasive malignancy (except non-melanomatous skin cancer) unless disease-free for a minimum of 3 years; (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)

  • Recurrent or multifocal malignant gliomas

  • Any site of distant disease (for example, drop metastases from the GBM tumor site)

  • Prior chemotherapy or radiosensitizers for cancers of the head and neck region; note that prior chemotherapy for a different cancer is allowable (except temozolomide)

  • Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment are not permitted

  • Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in overlap of radiation fields

  • Severe, active co-morbidity, defined as follows:

    • Unstable angina at step 2 registration
    • Transmural myocardial infarction within the last 6 months prior to step 2 registration
    • Evidence of recent myocardial infarction or ischemia by the findings of S-T elevations of >= 2 mm using the analysis of an electrocardiogram (EKG) performed within 28 days prior to step 2 registration (Note: EKG to be performed only if clinical suspicion of cardiac issue)
    • New York Heart Association grade II or greater congestive heart failure requiring hospitalization within 12 months prior to step 2 registration
    • Serious and inadequately controlled arrhythmia at step 2 registration
    • Serious or non-healing wound, ulcer or bone fracture or history of abdominal fistula, intra-abdominal abscess requiring major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to step 2 registration, with the exception of the craniotomy for surgical resection
    • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of step 2 registration
    • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for coagulation parameters are not required for entry into this protocol
    • Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of step 2 registration
    • Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is because the treatments involved in this protocol may be significantly immunosuppressive with potentially fatal outcomes in patients already immunosuppressed
    • Any other severe immunocompromised condition
    • Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the treating physician may put the patient at high risk for radiation toxicity
    • End-stage renal disease (ie, on dialysis or dialysis has been recommended)
    • Any other major medical illnesses or psychiatric treatments that in the investigator's opinion will prevent administration or completion of protocol therapy

  • Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic

  • Patients treated on any other therapeutic clinical protocols within 30 days prior to step 2 registration

  • Inability to undergo MRI (e.g., due to safety reasons, such as presence of a pacemaker, or severe claustrophobia)

  • Postoperative tumor plus surgical bed size exceeds 5 cm in maximum diameter

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Group 1 - Standard RT (Photon) (Arm A1)

Group 1 = Photon IMRT centers. Participants undergo standard-dose postoperative photon radiotherapy using 3-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) administered once daily, 5 days per week. Treatment consists of 46 Gy in 23 fractions followed by a sequential boost to a total dose of 60 Gy in 30 fractions. Participants receive concurrent temozolomide orally once daily during radiotherapy for up to 49 days and adjuvant temozolomide orally once daily on days 1-5 of each 28-day cycle for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
방사능: Photon Beam Radiation Therapy

daily fractions

다른 이름들:
  • 광자 EBRT
  • 광자 외부 빔 방사선 요법
  • 방사선, 광자 빔
  • 광자를 이용한 외부빔 방사선치료(시술)
  • 광자
  • 광자치료
의약품: Temozolomide

tablet

다른 이름들:
  • 테모다르
  • SCH 52365
  • 테모달
  • 템캐드
  • 메타졸라스톤
  • RP-46161
  • 테모메닥
  • TMZ
  • CCRG-81045
  • 이미다조[5,1-d]-1,2,3,5-테트라진-8-카르복스아미드, 3,4-디하이드로-3-메틸-4-옥소-
  • 엠앤비 39831
  • 글리오템
  • 테미졸
활성 비교기: Group 2 - Standard RT (Proton) (Arm A2)

Group 2 = Proton centers. Participants undergo the same standard-dose postoperative radiotherapy regimen described for Arm A1 but delivered using proton beam therapy. Participants receive concurrent and adjuvant temozolomide as described for Arm A1.
방사능: Photon Beam Radiation Therapy

daily fractions

다른 이름들:
  • 광자 EBRT
  • 광자 외부 빔 방사선 요법
  • 방사선, 광자 빔
  • 광자를 이용한 외부빔 방사선치료(시술)
  • 광자
  • 광자치료
의약품: Temozolomide

tablet

다른 이름들:
  • 테모다르
  • SCH 52365
  • 테모달
  • 템캐드
  • 메타졸라스톤
  • RP-46161
  • 테모메닥
  • TMZ
  • CCRG-81045
  • 이미다조[5,1-d]-1,2,3,5-테트라진-8-카르복스아미드, 3,4-디하이드로-3-메틸-4-옥소-
  • 엠앤비 39831
  • 글리오템
  • 테미졸
실험적: Group 1 - Intensified RT (Photon) (Arm B)

Group 1 = Photon IMRT centers. Patients undergo dose-escalated and -intensified photon IMRT QD, 5 days a week for a total of 30 fractions.

In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
방사능: Photon Beam Radiation Therapy

daily fractions

다른 이름들:
  • 광자 EBRT
  • 광자 외부 빔 방사선 요법
  • 방사선, 광자 빔
  • 광자를 이용한 외부빔 방사선치료(시술)
  • 광자
  • 광자치료
의약품: Temozolomide

tablet

다른 이름들:
  • 테모다르
  • SCH 52365
  • 테모달
  • 템캐드
  • 메타졸라스톤
  • RP-46161
  • 테모메닥
  • TMZ
  • CCRG-81045
  • 이미다조[5,1-d]-1,2,3,5-테트라진-8-카르복스아미드, 3,4-디하이드로-3-메틸-4-옥소-
  • 엠앤비 39831
  • 글리오템
  • 테미졸
실험적: Group 2 - Intensified RT (Proton) (Arm C)

Group 2 = Proton centers. Participants undergo the same radiotherapy regimen described for Arm B but delivered using proton beam therapy. The elective target volume receives 50 Gy(RBE) in 30 fractions, and the boost target volume receives 75 Gy(RBE) in 30 fractions. Participants receive concurrent and adjuvant temozolomide as described for Arm A1.
의약품: Temozolomide

tablet

다른 이름들:
  • 테모다르
  • SCH 52365
  • 테모달
  • 템캐드
  • 메타졸라스톤
  • RP-46161
  • 테모메닥
  • TMZ
  • CCRG-81045
  • 이미다조[5,1-d]-1,2,3,5-테트라진-8-카르복스아미드, 3,4-디하이드로-3-메틸-4-옥소-
  • 엠앤비 39831
  • 글리오템
  • 테미졸
방사능: Proton Beam Radiation Therapy

Undergo dose-escalated and -intensified proton beam radiation therapy

다른 이름들:
  • 양성자 방사선 치료
  • PBRT
  • 양성자
  • 양성자 EBRT
  • 양성자 외부 빔 방사선 요법
  • 방사선, 양성자 빔
  • 양성자 치료
  • 외부 빔 방사선 치료 양성자(시술)
  • 외부 빔 방사선 요법(양성자)

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Median Survival Time (Within Center Group)
기간: Randomization to death or last follow-up. Median follow-up at time of analysis was 16.2 months for Group 1 and 18.3 months for Group 2.

Comparisons occur between standard vs. intensified RT arms within group (Group 1: photon IMRT centers; Group 2: proton centers). Median survival times were estimated using the Kaplan-Meier method, censoring participants alive at the time of analysis. Comparisons occur between standard vs. intensified RT arms within group (Group 1: photon IMRT centers; Group 2: proton centers)
Randomization to death or last follow-up. Median follow-up at time of analysis was 16.2 months for Group 1 and 18.3 months for Group 2.

2차 결과 측정

결과 측정
측정값 설명
기간
Median Survival Time (Between Experimental Arms)
기간: Randomization to death or last follow-up. Median follow-up at time of analysis was 16.2 months for Group 1 and 18.3 months for Group 2.

Per the protocol, this outcome measure would be addressed only if both experimental (intensified RT) arms were statistically significantly different from their respective control (standard RT) arms, as defined in the primary outcome measure. If that condition were satisfied, the experimental (intensified RT) arms from each group would be compared with each other. Median survival times would be estimated using the Kaplan-Meier method, censoring participants alive at the time of analysis.
Randomization to death or last follow-up. Median follow-up at time of analysis was 16.2 months for Group 1 and 18.3 months for Group 2.
Median Progression-free Survival Time
기간: Randomization to progression, death, or last follow-up, whichever occurs first. Median follow-up at time of analysis was 16.2 months for Group 1 and 18.3 months for Group 2.

Progression is defined as any of the following: ≥25% increase in sum of the products of perpendicular diameters of enhancing lesions; any new lesion; or clinical deterioration, with the treating institution encouraged to differentiate progression from pseudoprogression and radionecrosis using surgical resection, biopsy, and alternative imaging accordingly. Median progression-free survival times were estimated using the Kaplan-Meier method, censoring participants alive at the time of analysis. Comparisons occur between standard vs. intensified RT arms within group (Group 1: photon IMRT centers; Group 2: proton centers).
Randomization to progression, death, or last follow-up, whichever occurs first. Median follow-up at time of analysis was 16.2 months for Group 1 and 18.3 months for Group 2.
Proportion of Participants With a Grade 3 or Higher Adverse Event
기간: Randomization to death or last follow-up. Median follow-up at time of analysis was 16.2 months for Group 1 and 18.3 months for Group 2.

Common Terminology Criteria for Adverse Events (version 4.0) grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Proportions were estimated using an exact binomial distribution. Comparisons occur between standard vs. intensified RT arms within group (Group 1: photon IMRT centers; Group 2: proton centers)
Randomization to death or last follow-up. Median follow-up at time of analysis was 16.2 months for Group 1 and 18.3 months for Group 2.
Change From Baseline in the M.D. Anderson Symptom Inventory Brain Tumor (MDASI-BT) Cognitive Factor Score After Cycle 3
기간: Baseline and end of cycle 3 of adjuvant temozolomide (approximately 24 weeks after start of chemoradiation)

The MD Anderson Symptom Inventory for brain tumor (MDASI-BT) is a 28-item multi-symptom patient-reported outcome measure assessing the severity of symptoms experienced by cancer patients and the interference with daily living caused by these symptoms, with 9 items specific to brain tumors. Each item ranges from 0 (best condition) to 10 (worst condition). A subscale score (Cognitive Factor) is the average of the subscale items, given that a specified minimum numbers of items were completed. A score worse than baseline by at least one is considered deterioration. Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline. Comparisons occur between standard vs. intensified RT arms within group (Group 1: photon IMRT centers; Group 2: proton centers).
Baseline and end of cycle 3 of adjuvant temozolomide (approximately 24 weeks after start of chemoradiation)
Change From Baseline in the M.D. Anderson Symptom Inventory Brain Tumor (MDASI-BT) Cognitive Factor Score After Cycle 12
기간: Baseline and end of cycle 12 of adjuvant temozolomide (approximately 60 weeks after start of chemoradiation)

The MD Anderson Symptom Inventory for brain tumor (MDASI-BT) is a 28-item multi-symptom patient-reported outcome measure assessing the severity of symptoms experienced by cancer patients and the interference with daily living caused by these symptoms, with 9 items specific to brain tumors. Each item ranges from 0 (best condition) to 10 (worst condition). A subscale score (Cognitive Factor) is the average of the subscale items, given that a specified minimum numbers of items were completed. A score worse than baseline by at least one is considered deterioration. Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline. Comparisons occur between standard vs. intensified RT arms within group (Group 1: photon IMRT centers; Group 2: proton centers).
Baseline and end of cycle 12 of adjuvant temozolomide (approximately 60 weeks after start of chemoradiation)
Change From Baseline in the Clinical Trial Battery Composite Standardized Score at End of Cycle 3
기간: Baseline and end of cycle 3 of adjuvant temozolomide (approximately 24 weeks after start of chemoradiation)

The Clinical Trial Battery Composite Standardized Score is calculated as the arithmetic mean of multiple standardized neurocognitive test scores assessing memory, processing speed, executive function, and verbal fluency. Scores are standardized (z-scores) adjusted for age, education, and gender, with a mean of 0 and standard deviation of 1. A participant must have the majority of component scores available to calculate the composite. Possible scores are standardized z-scores that typically range from approximately -3 to +3, with higher scores indicating a better outcome. Change is calculated as time point minus baseline such that a positive change value indicates improvement and a negative change value indicates decline. Comparisons are made between standard-dose and intensified radiation therapy arms within group (Group 1: photon IMRT centers; Group 2: proton centers).
Baseline and end of cycle 3 of adjuvant temozolomide (approximately 24 weeks after start of chemoradiation)
Change From Baseline in the Clinical Trial Battery Composite Standardized Score at End of Cycle 12
기간: Baseline and end of cycle 3 of adjuvant temozolomide (approximately 24 weeks after start of chemoradiation)

The Clinical Trial Battery Composite Standardized Score is calculated as the arithmetic mean of multiple standardized neurocognitive test scores assessing memory, processing speed, executive function, and verbal fluency. Scores are standardized (z-scores) adjusted for age, education, and gender, with a mean of 0 and standard deviation of 1. A participant must have the majority of component scores available to calculate the composite. Possible scores are standardized z-scores that typically range from approximately -3 to +3, with higher scores indicating a better outcome. Change is calculated as time point minus baseline such that a positive change value indicates improvement and a negative change value indicates decline. Comparisons are made between standard-dose and intensified radiation therapy arms within group (Group 1: photon IMRT centers; Group 2: proton centers).
Baseline and end of cycle 3 of adjuvant temozolomide (approximately 24 weeks after start of chemoradiation)

기타 결과 측정

결과 측정
측정값 설명
기간
CD4 Lymphopenia Count
기간: Baseline to up to 5 years

Mean CD4 lymphopenia count change from baseline to each follow-up collection timepoint.
Baseline to up to 5 years
Use of Magnetic Resonance Diffusion and Perfusion Imaging to Differentiate Between Tumor Progression and Pseudo-progression
기간: Baseline - cycle 4

Will be determined retrospectively following central review by an experienced neuro-radiologist blinded to the patient's outcome.
Baseline - cycle 4
Use of Magnetic Resonance Diffusion and Perfusion Imaging as Early Predictors of Overall Survival
기간: Baseline up to 12 months

Cox proportional hazard model will be used to analyze the effect of imaging markers on overall survival. Known prognostic factors and patient baseline characteristics will be included in the multivariate analyses as covariates.
Baseline up to 12 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

NRG Oncology

협력자

National Cancer Institute (NCI)

수사관

  • 수석 연구원: Minesh P Mehta, NRG Oncology

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2014년 12월 4일

기본 완료 (실제)

2025년 7월 7일

연구 완료 (추정된)

2030년 7월 7일

연구 등록 날짜

최초 제출

2014년 6월 27일

QC 기준을 충족하는 최초 제출

2014년 6월 27일

처음 게시됨 (추정된)

2014년 7월 1일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 1일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 9일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • NRG-BN001
  • U10CA180868 (미국 NIH 보조금/계약)
  • NRG-BN001 (기타 식별자: CTEP)
  • NCI-2014-01072 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
  • P50CA127001 (미국 NIH 보조금/계약)
  • NRG-BN001 (기타 식별자: NRG Oncology)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다